abstract: BACKGROUND: The foot and ankle surgeon can see @entity5 in the treatment of foot and ankle conditions. The purpose of this study was (1) to evaluate the demographics and presenting complaints of @entity0 diagnosed with @entity5 during an examination by a foot and ankle surgeon and (2) to identify the type and frequency of subsequent diagnosis of medical causes of @entity2 . METHODS: This was a retrospective study of @entity0 diagnosed with @entity5 in our practice between January 1997 and December 2008. Ninety-five @entity0 were identified, and demographic data, presenting complaints, and medical comorbidities were extracted from the medical record. Examination findings of decreased sensation to Semmes Weinstein 5.07 monofilament testing were documented, and electromyogram and nerve conduction study results were reviewed when available. Laboratory values were noted, as were neurologic evaluations performed to diagnose medical conditions associated with @entity5 . RESULTS: The most common presentation was foot @entity3 , in 36 @entity0 (38%). Ninety-one @entity0 had Semmes Weinstein 5.07 monofilament testing, with loss of protective sensation reported in 75 of the 91 tested (82%). Only 30 of the 95 @entity0 had electromyogram and nerve conduction study results available, with a test positive for @entity5 in 20 of the 30 tested. Thirty-two @entity0 were evaluated by a neurologist. A specific cause was identified in 12 of the 32 seen by a neurologist. Of the total group of 95 @entity0 , 31 @entity0 (33%) were diagnosed with a condition that may be associated with @entity5 . CONCLUSIONS: Thirty-three percent of the @entity0 presenting to our clinic and given a diagnosis of @entity5 were ultimately diagnosed with a medical cause of @entity2 -most commonly, @entity1 . For those @entity0 with @entity2 , a spectrum of disease was encountered, including @entity3 , @entity4 , infection, and Charcot neuroarthropathy. LEVEL OF EVIDENCE: Level IV, retrospective case series.

title: Evaluation of XXXX of Unknown Origin in an Outpatient Foot and Ankle Practice.

answer: @entity5


abstract: BACKGROUND AND AIM: This study aims to examine survival for @entity4 and its main subtypes, @entity2 ( @entity2 ), and @entity3 ( @entity3 ), in Germany and in the United States. METHODS: Data for @entity0 diagnosed in 1997-2010 were used from 10 population-based German @entity1 registries and compared to the data from the US Surveillance, Epidemiology and End Results (SEER) 13 registries database. @entity0 age 15-74 diagnosed with @entity4 were included in the analysis. Period analysis and modeled period analysis were used to estimate 5-year and 10-year relative survival (RS) in 2002-2010 and survival trends from 2002-2004 to 2008-2010. RESULTS: Overall, the database included 1534 and 2688 @entity0 diagnosed with @entity4 in 1997-2010 in Germany and in the United States, respectively. Survival was substantially higher for @entity2 (5-year and 10-year RS: 89.0% and 80.9% in Germany, 93.8% and 86.8% in the United States) than for @entity3 (67.5% and 59.2% in Germany, and 65.3% and 54.7% in the United States) in 2002-2010. Survival was slightly higher among female @entity0 and decreased by age for @entity4 combined and its main subtypes. A slight, nonsignificant, increase in the 5-year RS for @entity4 combined was observed in Germany and the United States, with increases in 5-year RS between 2002-2004 and 2008-2010 from 77.1% to 81.0% and from 77.3% to 82.0%, respectively. Five-year RS of @entity2 exceeded 90% in 2008-2010 in both countries. CONCLUSIONS: Five-year RS of @entity2 meanwhile exceeds 90% in both Germany and the United States, but @entity3 has remained below 70% in both countries.

title: Survival of @entity0 with XXXX in Germany and in the United States.

answer: @entity4


abstract: BACKGROUND AND AIM: This study aims to examine survival for @entity4 and its main subtypes, @entity2 ( @entity2 ), and @entity3 ( @entity3 ), in Germany and in the United States. METHODS: Data for @entity0 diagnosed in 1997-2010 were used from 10 population-based German @entity1 registries and compared to the data from the US Surveillance, Epidemiology and End Results (SEER) 13 registries database. @entity0 age 15-74 diagnosed with @entity4 were included in the analysis. Period analysis and modeled period analysis were used to estimate 5-year and 10-year relative survival (RS) in 2002-2010 and survival trends from 2002-2004 to 2008-2010. RESULTS: Overall, the database included 1534 and 2688 @entity0 diagnosed with @entity4 in 1997-2010 in Germany and in the United States, respectively. Survival was substantially higher for @entity2 (5-year and 10-year RS: 89.0% and 80.9% in Germany, 93.8% and 86.8% in the United States) than for @entity3 (67.5% and 59.2% in Germany, and 65.3% and 54.7% in the United States) in 2002-2010. Survival was slightly higher among female @entity0 and decreased by age for @entity4 combined and its main subtypes. A slight, nonsignificant, increase in the 5-year RS for @entity4 combined was observed in Germany and the United States, with increases in 5-year RS between 2002-2004 and 2008-2010 from 77.1% to 81.0% and from 77.3% to 82.0%, respectively. Five-year RS of @entity2 exceeded 90% in 2008-2010 in both countries. CONCLUSIONS: Five-year RS of @entity2 meanwhile exceeds 90% in both Germany and the United States, but @entity3 has remained below 70% in both countries.

title: Survival of XXXX with @entity4 in Germany and in the United States.

answer: @entity0


abstract: INTRODUCTION: Existing prediction rules for prospectively prognosticating early mortality following @entity1 ( @entity1 ) require clinical and/or laboratory data, and are rarely suitable for claims database analyses. We sought to develop a claims-based prediction rule that retrospectively classifies @entity1 @entity0 into low- or higher-risk in-hospital mortality categories. MATERIALS AND METHODS: We randomly assigned MarketScan database @entity0 admitted for @entity1 between April 2010 and September 2013 into derivation (80%) and validation (20%) cohorts. A prediction rule (In-hospital Mortality for @entity1 using Claims daTa or IMPACT) was derived using multivariable logistic regression, with in-hospital mortality as the dependent variable and demographic/comorbidity data available in claims databases as independent variables. In-hospital mortality rates for low- and higher-risk @entity0 were compared across the derivation and validation cohorts, and prediction rule performance was assessed by evaluating sensitivity and specificity estimates. RESULTS: A total of 27,833 @entity0 admitted for @entity1 were included. The IMPACT rule consisted of 12 risk factors, and categorized 46% of @entity0 as low-risk in both cohorts. @entity0 classified as low-risk by IMPACT (defined as an estimated in-hospital mortality risk  <=1.5%) had average in-hospital mortality rates of 0.81% (95% confidence interval [CI], 0.65-1.00) in the derivation and 0.77% (95% CI, 0.50-1.18) in the validation cohort. Higher-risk @entity0 had average in-hospital mortality rates of 4.61% (95% CI, 4.25-5.01) and 5.02% (95% CI, 4.30-5.85), respectively. The IMPACT rule had high sensitivity for classifying in-hospital mortality risk (0.87 in both cohorts), but moderate specificity (0.47 for both cohorts). LIMITATIONS: We were unable to assess 30 day mortality as an endpoint. IMPACT was only validated in an internal sample. CONCLUSIONS: The IMPACT prediction rule may be able to retrospectively classify @entity1 @entity0 ' in-hospital mortality risk with high sensitivity and moderate specificity.

title: Derivation and validation of the In-hospital Mortality for XXXX using Claims daTa (IMPACT) prediction rule.

answer: @entity1


abstract: OBJECTIVES: To evaluate the accuracy of the radiopharmaceutical @entity3 combined with positron emission tomography/computer tomography ( @entity1 -PET/CT) in @entity2 ( @entity2 ) staging in newly diagnosed prostate cancer cases. A second aim was to evaluate the potential discriminative properties of @entity1 -PET/CT in clinical routine. @entity0 AND METHODS: In a prospective comparative study, from July 2010 to June 2013, 53 @entity0 with newly histologically diagnosed intermediate- or high-risk prostate cancer underwent @entity1 -PET/CT investigation at one regional centre before laparoscopic extended pelvic @entity2 dissection (ePLND) at one referral centre. The sensitivity, specificity and accuracy of @entity1 -PET/CT were calculated. Comparisons were made between true-positive and false-negative PET/CT cases to identify differences in the clinical parameters: PSA level, Gleason status, lymph metastasis burden and size, calculated risk of @entity2 involvement, and curative treatment decisions. RESULTS: In all, 26 @entity0 had surgically/histologically confirmed @entity2 metastasis ( @entity2 +). @entity1 -PET/CT was true positive in 10 @entity0 , false positive in one, false negative in 16, and true negative in 26. The individual sensitivity was 38%, specificity 96%, and accuracy 68%. The @entity1 -PET/CT positive cases had significantly more involved LNs (mean 7.9 vs 2.4, P < 0.001) with larger cancer diameters (14.1 vs 4.9  mm, P = 0.001) and fewer eventually had treatment with curative intent (40% vs 94%, P <0.005), although we lack long-term outcome data. CONCLUSION: @entity1 -PET/CT has too low a sensitivity for routine @entity2 staging but the specificity is high. The @entity1 -PET/CT positive cases have a very high burden of @entity2 spread.

title: Laparoscopic extended pelvic @entity2 ( @entity2 ) dissection as validation of the performance of XXXX positron emission tomography/computer tomography in the detection of @entity2 metastasis in intermediate- and high-risk prostate cancer.

answer: @entity3


abstract: OBJECTIVES: To evaluate the accuracy of the radiopharmaceutical @entity3 combined with positron emission tomography/computer tomography ( @entity1 -PET/CT) in @entity2 ( @entity2 ) staging in newly diagnosed prostate cancer cases. A second aim was to evaluate the potential discriminative properties of @entity1 -PET/CT in clinical routine. @entity0 AND METHODS: In a prospective comparative study, from July 2010 to June 2013, 53 @entity0 with newly histologically diagnosed intermediate- or high-risk prostate cancer underwent @entity1 -PET/CT investigation at one regional centre before laparoscopic extended pelvic @entity2 dissection (ePLND) at one referral centre. The sensitivity, specificity and accuracy of @entity1 -PET/CT were calculated. Comparisons were made between true-positive and false-negative PET/CT cases to identify differences in the clinical parameters: PSA level, Gleason status, lymph metastasis burden and size, calculated risk of @entity2 involvement, and curative treatment decisions. RESULTS: In all, 26 @entity0 had surgically/histologically confirmed @entity2 metastasis ( @entity2 +). @entity1 -PET/CT was true positive in 10 @entity0 , false positive in one, false negative in 16, and true negative in 26. The individual sensitivity was 38%, specificity 96%, and accuracy 68%. The @entity1 -PET/CT positive cases had significantly more involved LNs (mean 7.9 vs 2.4, P < 0.001) with larger cancer diameters (14.1 vs 4.9  mm, P = 0.001) and fewer eventually had treatment with curative intent (40% vs 94%, P <0.005), although we lack long-term outcome data. CONCLUSION: @entity1 -PET/CT has too low a sensitivity for routine @entity2 staging but the specificity is high. The @entity1 -PET/CT positive cases have a very high burden of @entity2 spread.

title: Laparoscopic extended pelvic XXXX ( @entity2 ) dissection as validation of the performance of @entity3 positron emission tomography/computer tomography in the detection of @entity2 metastasis in intermediate- and high-risk prostate cancer.

answer: @entity2


abstract: OBJECTIVES: To evaluate the accuracy of the radiopharmaceutical @entity3 combined with positron emission tomography/computer tomography ( @entity1 -PET/CT) in @entity2 ( @entity2 ) staging in newly diagnosed prostate cancer cases. A second aim was to evaluate the potential discriminative properties of @entity1 -PET/CT in clinical routine. @entity0 AND METHODS: In a prospective comparative study, from July 2010 to June 2013, 53 @entity0 with newly histologically diagnosed intermediate- or high-risk prostate cancer underwent @entity1 -PET/CT investigation at one regional centre before laparoscopic extended pelvic @entity2 dissection (ePLND) at one referral centre. The sensitivity, specificity and accuracy of @entity1 -PET/CT were calculated. Comparisons were made between true-positive and false-negative PET/CT cases to identify differences in the clinical parameters: PSA level, Gleason status, lymph metastasis burden and size, calculated risk of @entity2 involvement, and curative treatment decisions. RESULTS: In all, 26 @entity0 had surgically/histologically confirmed @entity2 metastasis ( @entity2 +). @entity1 -PET/CT was true positive in 10 @entity0 , false positive in one, false negative in 16, and true negative in 26. The individual sensitivity was 38%, specificity 96%, and accuracy 68%. The @entity1 -PET/CT positive cases had significantly more involved LNs (mean 7.9 vs 2.4, P < 0.001) with larger cancer diameters (14.1 vs 4.9  mm, P = 0.001) and fewer eventually had treatment with curative intent (40% vs 94%, P <0.005), although we lack long-term outcome data. CONCLUSION: @entity1 -PET/CT has too low a sensitivity for routine @entity2 staging but the specificity is high. The @entity1 -PET/CT positive cases have a very high burden of @entity2 spread.

title: Laparoscopic extended pelvic @entity2 ( XXXX ) dissection as validation of the performance of @entity3 positron emission tomography/computer tomography in the detection of @entity2 metastasis in intermediate- and high-risk prostate cancer.

answer: @entity2


abstract: OBJECTIVES: To evaluate the accuracy of the radiopharmaceutical @entity3 combined with positron emission tomography/computer tomography ( @entity1 -PET/CT) in @entity2 ( @entity2 ) staging in newly diagnosed prostate cancer cases. A second aim was to evaluate the potential discriminative properties of @entity1 -PET/CT in clinical routine. @entity0 AND METHODS: In a prospective comparative study, from July 2010 to June 2013, 53 @entity0 with newly histologically diagnosed intermediate- or high-risk prostate cancer underwent @entity1 -PET/CT investigation at one regional centre before laparoscopic extended pelvic @entity2 dissection (ePLND) at one referral centre. The sensitivity, specificity and accuracy of @entity1 -PET/CT were calculated. Comparisons were made between true-positive and false-negative PET/CT cases to identify differences in the clinical parameters: PSA level, Gleason status, lymph metastasis burden and size, calculated risk of @entity2 involvement, and curative treatment decisions. RESULTS: In all, 26 @entity0 had surgically/histologically confirmed @entity2 metastasis ( @entity2 +). @entity1 -PET/CT was true positive in 10 @entity0 , false positive in one, false negative in 16, and true negative in 26. The individual sensitivity was 38%, specificity 96%, and accuracy 68%. The @entity1 -PET/CT positive cases had significantly more involved LNs (mean 7.9 vs 2.4, P < 0.001) with larger cancer diameters (14.1 vs 4.9  mm, P = 0.001) and fewer eventually had treatment with curative intent (40% vs 94%, P <0.005), although we lack long-term outcome data. CONCLUSION: @entity1 -PET/CT has too low a sensitivity for routine @entity2 staging but the specificity is high. The @entity1 -PET/CT positive cases have a very high burden of @entity2 spread.

title: Laparoscopic extended pelvic @entity2 ( @entity2 ) dissection as validation of the performance of @entity3 positron emission tomography/computer tomography in the detection of XXXX metastasis in intermediate- and high-risk prostate cancer.

answer: @entity2


abstract: UNASSIGNED: Background @entity6 ( @entity6 ) is a @entity3 caused by ingestion of the eggs of the parasitic cestode @entity7 ( @entity7 ). In severe cases liver transplantation (LT) may represent the only possibility of survival and cure. METHODS: @entity0 undergoing LT associated with hepatic @entity6 at our institution between April 2011 and October 2014 were investigated retrospectively. The clinical findings of the 27 @entity0 who participated in the study were noted. The Kaplan-Meier and Chi-Square tests were used to investigate the effect of these characteristics on survival and mortality. RESULTS: Live donor LT was performed on 20 @entity0 (74.1%) and deceased LT on 7(25.9%). Hilar invasion was the most common indication (14 @entity0 , 51.9%) for transplantation. The @entity0 were followed up for 16.1  11.4 months. The overall survival rate was 77.8%. Primary non-function developed only in 2 @entity0 in the post-transplantation period. Six @entity0 died during monitoring, the most common cause of death being the @entity5 (3 @entity0 ). The relationship between the mortality rate of the @entity0 and the invasion of the bile duct and/or portal vein by @entity1 was found to be statistically significant (p=0.024 and p=0.043, respectively). CONCLUSIONS: According to the PNM Staging, when the @entity6 exceeds the resectability limits, the only alternative for the treatment of the disease is liver transplantation. However, different from the liver transplantation due to @entity2 , it is extremely difficult to perform a transplantation in @entity6 because of the invasive characteristics of it. In order to decrease the difficulty of the operation and the postoperative mortality, the intracystic abscess and @entity4 which occur due to @entity6 must be treated via medical and percutaneous method before the transplantation. This article is protected by copyright. All rights reserved.

title: Liver transplantation for XXXX in an endemic region.

answer: @entity6


abstract: PURPOSE: To determine whether adjunctive @entity3 ( @entity4 ) or amniotic membrane transplantation (AMT) improve the outcomes of @entity2 valve (AGV) implantation. METHODS: This double-blind, stratified, 3-armed randomized clinical trial includes 75 eyes of 75 @entity0 aged 7 to 75 years with @entity2 . Eligible subjects underwent stratified block randomization; eyes were first stratified to surgery in the superior or inferior quadrants based on feasibility; in each subgroup, eyes were randomly assigned to the study arms using random blocks: conventional AGV implantation (group A, 25 eyes), AGV with @entity4 (group B, 25 eyes), and AGV with AMT (group C, 25 eyes). RESULTS: The 3 study groups were comparable regarding baseline characteristics and mean follow-up (P=0.288). A total of 68 @entity0 including 23 eyes in group A, 25 eyes in group B, and 20 eyes group C completed the follow-up period and were analyzed. Intraocular pressure was lower in the @entity4 group only 3 weeks postoperatively (P=0.04) but comparable at other time intervals. Overall success rate was comparable in the 3 groups at 12 months (P=0.217). The number of eyes requiring medications (P=0.30), time to initiation of medications (P=0.13), and number of medications (P=0.22) were comparable. @entity1 phase was slightly but insignificantly more common with standard surgery (82%) as compared with @entity4 -augmented (60%) and AMT-augmented (70%) procedures (P=0.23). Complications were comparable over 1 year (P=0.28). CONCLUSIONS: Although adjunctive @entity4 and AMT were safe during AGV implantation, they did not influence success rates or intraocular pressure outcomes. Complications, including @entity1 phase, were also comparable.

title: Adjunctive XXXX or Amniotic Membrane Transplantation for Ahmed @entity2 : A Randomized Clinical Trial.

answer: @entity3


abstract: PURPOSE: To determine whether adjunctive @entity3 ( @entity4 ) or amniotic membrane transplantation (AMT) improve the outcomes of @entity2 valve (AGV) implantation. METHODS: This double-blind, stratified, 3-armed randomized clinical trial includes 75 eyes of 75 @entity0 aged 7 to 75 years with @entity2 . Eligible subjects underwent stratified block randomization; eyes were first stratified to surgery in the superior or inferior quadrants based on feasibility; in each subgroup, eyes were randomly assigned to the study arms using random blocks: conventional AGV implantation (group A, 25 eyes), AGV with @entity4 (group B, 25 eyes), and AGV with AMT (group C, 25 eyes). RESULTS: The 3 study groups were comparable regarding baseline characteristics and mean follow-up (P=0.288). A total of 68 @entity0 including 23 eyes in group A, 25 eyes in group B, and 20 eyes group C completed the follow-up period and were analyzed. Intraocular pressure was lower in the @entity4 group only 3 weeks postoperatively (P=0.04) but comparable at other time intervals. Overall success rate was comparable in the 3 groups at 12 months (P=0.217). The number of eyes requiring medications (P=0.30), time to initiation of medications (P=0.13), and number of medications (P=0.22) were comparable. @entity1 phase was slightly but insignificantly more common with standard surgery (82%) as compared with @entity4 -augmented (60%) and AMT-augmented (70%) procedures (P=0.23). Complications were comparable over 1 year (P=0.28). CONCLUSIONS: Although adjunctive @entity4 and AMT were safe during AGV implantation, they did not influence success rates or intraocular pressure outcomes. Complications, including @entity1 phase, were also comparable.

title: Adjunctive @entity3 or Amniotic Membrane Transplantation for Ahmed XXXX : A Randomized Clinical Trial.

answer: @entity2


abstract: BACKGROUND: @entity8 ( @entity8 ) is a common genetic @entity4 characterized by @entity2 , @entity3 , and impaired ventricular relaxation. The exact mechanisms by which @entity1 is caused remain unknown. HYPOTHESIS: Circulating @entity9 is related to poor prognosis in @entity8 . METHODS: We compared @entity9 levels of 49 @entity8 @entity0 with those of 40 non- @entity8 @entity0 . We followed the @entity0 with @entity8 for 18 months and divided them into 2 groups: low @entity9 ( <=4877 pg/mL) and high @entity9 (>4877 pg/mL). We compared the 2 groups in terms of @entity10 ( @entity10 ), echocardiographic parameters, and clinical outcomes including @entity5 , @entity7 , implantable cardioverter-defibrillator implantation, hospitalization, New York Heart Association (NYHA) class, @entity6 , and mortality. RESULTS: The @entity8 @entity0 had higher @entity9 levels than those in the control group (P = 0.005). In the follow-up, those in the high @entity9 group had higher @entity10 levels, larger left-atrial size, thicker interventricular septum, NYHA class, more hospitalizations, and a greater number of clinical adverse events (P < 0.001, P = 0.01, P < 0.001, P = 0.002, P < 0.001 and P = 0.003, respectively). @entity9 level of >4877 pg/mL can predict adverse events with a specificity of 75% and a sensitivity of 72% (P = 0.014). In multivariate regression analysis, @entity9 , @entity10 , and interventricular septum thickness were significantly associated with adverse events (P = 0.028, P = 0.030, and P = 0.034, respectively). CONCLUSIONS: The @entity9 level is higher in @entity8 @entity0 and associated with a poor prognosis in @entity8 .

title: Increased Transforming Growth Factor-b Levels Associated With Cardiac Adverse Events in XXXX .

answer: @entity8


abstract: UNASSIGNED: @entity1 ( @entity1 ) are significantly high in the Lebanese population with the two most predominant forms being @entity6 and @entity0 . The purpose of our study was to assess the association of a spectrum of CVD related genes and combined state of @entity2 ( @entity2 ) in unrelated Lebanese. Twelve polymorphisms were studied by multiplex PCR and reverse hybridization of DNA from 171 healthy individuals and 144 @entity2 subjects. Two genes were significantly associated with @entity2 : @entity7 (OR: 9.20, P<0.0001) and @entity8 (OR: 2.29, P = 0.007), respectively with the occurrence of the risky alleles "Del" and "4G". The frequencies of the Del and 4G alleles were found to be 0.98 and 0.90 in the @entity2 group versus 0.84 and 0.79 in the healthy group, respectively. Serum @entity7 activity and PAI-I increased significantly with Del/Del and 4G/5G genotypes. The co-expression of Del/4G(+/+) was detected in 113 out of 171 (66.0%) controls and 125 out of 144 (86.8%) @entity2 subjects. Del/4G(-/-) was detected in only 6 (3.5%) controls and undetected in the @entity2 group. Three @entity0 related genes [FV(Leiden), @entity14 ( @entity16 ) and FXIII( @entity15 )] were significantly related to the prominence of the co-expression of Del/4G(+/+). A range of 2 to 8 combined polymorphisms co-expressed per subject where 5 mutations were the most detected. In Del/4G(+/+) subjects, peripheral blood mononuclear cells (PBMCs) produced significant elevated levels of @entity4 and @entity3 contrary to @entity5 , and no variations occurred for @entity11 . @entity7 inhibitor ( @entity10 ) in combination with @entity13 ( @entity9 ) and not alone reversed significantly the situation. This first report from Lebanon sheds light on an additional genetic predisposition of a complex spectrum of genes involved in CVD and suggests that the most requested gene @entity12 by physicians may not be sufficient to diagnose eventual future problems that can occur in the cardiovascular system. Subjects expressing the double mutations (Del/4G) are at high risk for the onset of @entity1 .

title: High Incidence of XXXX / @entity8 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of @entity7 Inhibitor and Statin.

answer: @entity7


abstract: UNASSIGNED: @entity1 ( @entity1 ) are significantly high in the Lebanese population with the two most predominant forms being @entity6 and @entity0 . The purpose of our study was to assess the association of a spectrum of CVD related genes and combined state of @entity2 ( @entity2 ) in unrelated Lebanese. Twelve polymorphisms were studied by multiplex PCR and reverse hybridization of DNA from 171 healthy individuals and 144 @entity2 subjects. Two genes were significantly associated with @entity2 : @entity7 (OR: 9.20, P<0.0001) and @entity8 (OR: 2.29, P = 0.007), respectively with the occurrence of the risky alleles "Del" and "4G". The frequencies of the Del and 4G alleles were found to be 0.98 and 0.90 in the @entity2 group versus 0.84 and 0.79 in the healthy group, respectively. Serum @entity7 activity and PAI-I increased significantly with Del/Del and 4G/5G genotypes. The co-expression of Del/4G(+/+) was detected in 113 out of 171 (66.0%) controls and 125 out of 144 (86.8%) @entity2 subjects. Del/4G(-/-) was detected in only 6 (3.5%) controls and undetected in the @entity2 group. Three @entity0 related genes [FV(Leiden), @entity14 ( @entity16 ) and FXIII( @entity15 )] were significantly related to the prominence of the co-expression of Del/4G(+/+). A range of 2 to 8 combined polymorphisms co-expressed per subject where 5 mutations were the most detected. In Del/4G(+/+) subjects, peripheral blood mononuclear cells (PBMCs) produced significant elevated levels of @entity4 and @entity3 contrary to @entity5 , and no variations occurred for @entity11 . @entity7 inhibitor ( @entity10 ) in combination with @entity13 ( @entity9 ) and not alone reversed significantly the situation. This first report from Lebanon sheds light on an additional genetic predisposition of a complex spectrum of genes involved in CVD and suggests that the most requested gene @entity12 by physicians may not be sufficient to diagnose eventual future problems that can occur in the cardiovascular system. Subjects expressing the double mutations (Del/4G) are at high risk for the onset of @entity1 .

title: High Incidence of @entity7 / @entity8 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of XXXX Inhibitor and Statin.

answer: @entity7


abstract: UNASSIGNED: @entity1 ( @entity1 ) are significantly high in the Lebanese population with the two most predominant forms being @entity6 and @entity0 . The purpose of our study was to assess the association of a spectrum of CVD related genes and combined state of @entity2 ( @entity2 ) in unrelated Lebanese. Twelve polymorphisms were studied by multiplex PCR and reverse hybridization of DNA from 171 healthy individuals and 144 @entity2 subjects. Two genes were significantly associated with @entity2 : @entity7 (OR: 9.20, P<0.0001) and @entity8 (OR: 2.29, P = 0.007), respectively with the occurrence of the risky alleles "Del" and "4G". The frequencies of the Del and 4G alleles were found to be 0.98 and 0.90 in the @entity2 group versus 0.84 and 0.79 in the healthy group, respectively. Serum @entity7 activity and PAI-I increased significantly with Del/Del and 4G/5G genotypes. The co-expression of Del/4G(+/+) was detected in 113 out of 171 (66.0%) controls and 125 out of 144 (86.8%) @entity2 subjects. Del/4G(-/-) was detected in only 6 (3.5%) controls and undetected in the @entity2 group. Three @entity0 related genes [FV(Leiden), @entity14 ( @entity16 ) and FXIII( @entity15 )] were significantly related to the prominence of the co-expression of Del/4G(+/+). A range of 2 to 8 combined polymorphisms co-expressed per subject where 5 mutations were the most detected. In Del/4G(+/+) subjects, peripheral blood mononuclear cells (PBMCs) produced significant elevated levels of @entity4 and @entity3 contrary to @entity5 , and no variations occurred for @entity11 . @entity7 inhibitor ( @entity10 ) in combination with @entity13 ( @entity9 ) and not alone reversed significantly the situation. This first report from Lebanon sheds light on an additional genetic predisposition of a complex spectrum of genes involved in CVD and suggests that the most requested gene @entity12 by physicians may not be sufficient to diagnose eventual future problems that can occur in the cardiovascular system. Subjects expressing the double mutations (Del/4G) are at high risk for the onset of @entity1 .

title: High Incidence of @entity7 / XXXX in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of @entity7 Inhibitor and Statin.

answer: @entity8


abstract: Cigarette smoking is associated with an increased risk of @entity7 , chronic @entity4 , and @entity0 , all of which may be modulated by endogenous @entity3 (NO). We have investigated whether cigarette smoking reduces the production of endogenous NO. We compared exhalations of 41 current cigarette smokers with normal lung function and 73 age-matched non-smoking controls. Peak exhaled NO levels were measured by a modified chemiluminescence analyzer. The effects of inhaling a single cigarette in smokers were also measured. In control subjects we also measured the effects of inhalation of NO itself and @entity5 , both constituents of @entity2 smoke. Peak exhaled NO concentrations were significantly reduced in smokers (42 +/- 3.9 compared with 88 +/- 2.7 parts per billion in nonsmokers, p < 0.01), with a significant relation between the exhaled NO and cigarette consumption (r = 0.77, p < 0.001). Smoking a single cigarette also significantly (p < 0.02), but transiently, reduced exhaled NO. Inhalation of @entity5 and NO had no effect on exhaled NO in normal subjects. Cigarette smoking decreased exhaled NO, suggesting that it may inhibit the enzyme NO synthase. Since endogenous NO is important in defending the respiratory tract against @entity1 , in counteracting bronchoconstriction and vasoconstriction, and in inhibiting @entity6 , this effect may contribute to the increased risks of chronic respiratory and @entity0 in cigarette smokers.

title: Acute and chronic effects of cigarette smoking on exhaled XXXX .

answer: @entity3


abstract: 1. A successful @entity0 "venous return (VR)" model is described, in which all hemodynamic parameters were stable for about an hour, by minimizing extracorporeal circuit primed with dextran (DX) so that the dilution of the blood was kept about 33%. 2. Increases in VR by @entity3 (1 micrograms/kg) and dose-dependent decreases in VR by @entity4 (1-30 micrograms/kg) were clearly observed. 3. While 1 microgram/kg of @entity2 produced a small, but significant decrease in VR, only a tendency for decrease was observed with higher doses which produced a @entity1 . 4. @entity6 (1 microgram/kg) caused a small decrease in VR. However, higher doses that produced a large and persistent @entity1 produced an increase in VR due probably to intense reflex translocation of the blood. The increase in VR was reversed with @entity5 , a beta-blocker with alpha-blocking activity.

title: Use of dextran-primed extracorporeal circuit in the XXXX model for venous return: with special references to the effects of two dihydropyridine-type Ca2+ channel blockers.

answer: @entity0


abstract: Importance: The most widely used surgical interventions for pediatric unilateral vocal @entity2 include injection laryngoplasty, thyroplasty, and laryngeal reinnervation. Despite increasing interest in surgical interventions for unilateral vocal @entity2 in @entity0 , the surgical outcomes data in @entity0 are scarce. Objective: To appraise and summarize the available evidence for pediatric unilateral vocal @entity2 surgical strategies. Evidence Review: MEDLINE (1946-2014) and EMBASE (1980-2014) were searched for publications that described the results of laryngoplasty, thyroplasty, or laryngeal reinnervation for pediatric unilateral vocal @entity2 . Further studies were identified from bibliographies of relevant studies, gray literature, and annual scientific assemblies. Two reviewers independently appraised the selected studies for quality, level of evidence, and risk of bias as well as extracted data, including unilateral vocal @entity2 origin, voice outcomes, swallowing outcomes, and adverse events. Findings: Of 366 identified studies, the inclusion criteria were met by 15 studies: 6 observational studies, 6 case series, and 3 case reports. All 36 @entity0 undergoing laryngeal reinnervation (8 studies) had improvement or resolution of @entity4 . Of 31 @entity0 receiving injection laryngoplasty (6 studies), most experienced improvement in voice quality, speech, swallowing, @entity3 , and glottic closure. Of 12 @entity0 treated by thyroplasty (5 studies), 2 experienced resolution of @entity4 , 4 had some improvement, and 4 had no improvement (2 @entity0 had undocumented outcomes). Thyroplasty resolved or improved @entity3 in 7 of 8 @entity0 . Conclusions and Relevance: Published studies suggest that reinnervation may be the most effective surgical intervention for @entity0 with @entity4 ; however, long-term follow-up data are lacking. With the exception of @entity1 injections, injection laryngoplasty was reported to be a relatively safe, nonpermanent, and effective option for most @entity0 with @entity4 . Thyroplasty appears to have fallen out favor in recent years because of difficulty in performing this procedure in @entity0 under local anesthesia, but it continues to be a viable option for @entity0 with @entity3 .

title: Surgical Interventions for Pediatric Unilateral Vocal XXXX : A Systematic Review.

answer: @entity2


abstract: BACKGROUND: For acute @entity3 caused by bacteria, colonization in the respiratory tracts is often the first sign, although nasopharynx is the major source of secretions containing pathogens. To understand the pathogenesis of @entity8 , it is important to analyze the establishment of nasopharyngeal bacterial colonization. METHODS: @entity0 with nasopharyngeal swabs were examined at the age of 1, 2, 4, 6 and 12 months for the detection of pathogens, including @entity1 , @entity7 , @entity6 , @entity5 and @entity2 . The methods used for detection were bacterial culture and multiplex polymerase chain reaction. RESULTS: From January 2012 to August 2013, a total of 320 neonates were enrolled, and 120 of them completed the first 12-month study. @entity2 was the most common pathogen at all 5 time points while the rates declined; in contrast, the other 4 increased during the first year of life. Of our series, the multiplex polymerase chain reaction detection rates were higher than those of bacterial culture. More than 50% of @entity2 was @entity4 -resistant, and the trend decreased in the same period. In the analysis of factors associated with the development of @entity0 wheeze, @entity0 with maternal atopy [odds ratio (OR): 3.26; 95% confidence interval (CI): 1.20-8.88; P = 0.02] and pneumococcal colonization (OR: 15.64; 95% CI: 3.25-75.35; P = 0.001) had higher rates of wheeze. CONCLUSIONS: Bacterial interactions may result in differing pathogen prevalence in the first year of life. In addition, nasopharyngeal pneumococcal colonization may have an effect on the risk of @entity0 wheeze. The result could help clinicians to clarify the relation between bacterial colonization and respiratory illnesses in infancy.

title: Pathogenic Bacterial Nasopharyngeal Colonization and Its Impact on XXXX in the First Year of Life: The PATCH Birth Cohort Study.

answer: @entity3


abstract: Veno-arterial plasma concentration differences and regional organ plasma flows were used to quantify the relative amounts of @entity4 ( @entity6 ) contributed by various sites into the peripheral circulation. Positive venoarterial concentration gradients were found in the hepatosplanchnic, forearm, cardiac and jugular vessels in the healthy subjects. The renal circulation was determined to be the principal site of @entity6 clearance, extracting 18 +/- 2 nmol/min. The gut was the greatest contributor to the total @entity6 plasma pool with the relative contributions of the various organs being as follows: hepatosplanchnic organs 58%, skeletal muscle 26%, brain 6% and the heart 3%. The source of @entity6 stemming from these regional beds remains unknown, it may derive from @entity2 taken up by and deaminated in ubiquitous endothelial cells, enterochromaffin cells of the gut, peripheral serotonergic nerves, @entity2 turnover in platelets or perhaps the metabolism of @entity2 taken up by sympathetic nerves. To test the latter hypothesis we examined 23 @entity0 with chronic @entity1 and 9 @entity0 with @entity5 to investigate the possible effects of sympathetic nervous system overactivity and underactivity on peripheral @entity6 production and plasma @entity6 concentration. The resting arterial plasma @entity6 concentration in the @entity1 @entity0 was increased three-fold. This elevated plasma @entity6 concentration was attributable to an increased rate of whole body @entity6 production. The arterial @entity6 plasma concentration in the @entity7 @entity0 was paradoxically elevated, being 70% greater than that of the healthy subjects. The increased @entity6 plasma concentration in these @entity0 was accounted for by a reduction in @entity6 plasma clearance. In all subjects studied there was a weak relationship only between total body @entity3 spillover to plasma and the arterial @entity6 plasma concentration. We found that in healthy subjects the overflow of @entity6 into the hepatic vein was significantly related to the underlying degree of sympathetic activity. It can be concluded that @entity6 is produced at a number of sites throughout the body with the arterial plasma concentration being dependent on both the level of production and plasma clearance. By far the majority of @entity6 in plasma is derived from the gut with only minimal contribution from the brain.

title: Regional XXXX production in @entity0 .

answer: @entity4


abstract: Veno-arterial plasma concentration differences and regional organ plasma flows were used to quantify the relative amounts of @entity4 ( @entity6 ) contributed by various sites into the peripheral circulation. Positive venoarterial concentration gradients were found in the hepatosplanchnic, forearm, cardiac and jugular vessels in the healthy subjects. The renal circulation was determined to be the principal site of @entity6 clearance, extracting 18 +/- 2 nmol/min. The gut was the greatest contributor to the total @entity6 plasma pool with the relative contributions of the various organs being as follows: hepatosplanchnic organs 58%, skeletal muscle 26%, brain 6% and the heart 3%. The source of @entity6 stemming from these regional beds remains unknown, it may derive from @entity2 taken up by and deaminated in ubiquitous endothelial cells, enterochromaffin cells of the gut, peripheral serotonergic nerves, @entity2 turnover in platelets or perhaps the metabolism of @entity2 taken up by sympathetic nerves. To test the latter hypothesis we examined 23 @entity0 with chronic @entity1 and 9 @entity0 with @entity5 to investigate the possible effects of sympathetic nervous system overactivity and underactivity on peripheral @entity6 production and plasma @entity6 concentration. The resting arterial plasma @entity6 concentration in the @entity1 @entity0 was increased three-fold. This elevated plasma @entity6 concentration was attributable to an increased rate of whole body @entity6 production. The arterial @entity6 plasma concentration in the @entity7 @entity0 was paradoxically elevated, being 70% greater than that of the healthy subjects. The increased @entity6 plasma concentration in these @entity0 was accounted for by a reduction in @entity6 plasma clearance. In all subjects studied there was a weak relationship only between total body @entity3 spillover to plasma and the arterial @entity6 plasma concentration. We found that in healthy subjects the overflow of @entity6 into the hepatic vein was significantly related to the underlying degree of sympathetic activity. It can be concluded that @entity6 is produced at a number of sites throughout the body with the arterial plasma concentration being dependent on both the level of production and plasma clearance. By far the majority of @entity6 in plasma is derived from the gut with only minimal contribution from the brain.

title: Regional @entity4 production in XXXX .

answer: @entity0


abstract: The duration of @entity5 and @entity3 after high-dose chemotherapy has improved since the introduction of myeloid growth factors and peripheral blood progenitor cells (PBPC), yet there remains a subset of @entity1 who have delayed @entity6 recovery. Currently, there ar no established, reliable parameters which may be used to guide stem cell harvests. We investigated the utility of measuring harvested @entity7 positive cell populations by flow cytometry. From March 1990 to July 1993, 30 @entity1 with @entity0 underwent therapy with high-dose @entity2 and thiotepa and stem cell rescue. @entity1 received either @entity2 (CY) mobilized PBPC or CY/ @entity4 mobilized PBPC. The number of harvested @entity7 + cell and CFU-GM (colony forming units-granulocyte macrophage) were quantitated for each stem cell produce. There ar complete @entity7 data for 21 @entity1 and complete CFU-GM data for 20 @entity1 . There was a significantly delayed neutrophil recovery in those @entity1 reinfused with < 0.75 x 10(6) @entity7 + cells/kg body weight (median days 22) compared with @entity1 reinfused with > 0.75 x 10(6)/kg (median days 12, P = 0.0004); a similar trend was seen with platelet recovery (median 135 days vs 18 days, respectively, P = 0.002). With neutrophil recovery, there was no improvement in time to engraftment with a large number of reinfused @entity7 + cells, but there was a trend towards shortened platelet recovery when the number of reinfused @entity7 + cells exceeded 2.0 x 10(6)/kg (median 15 days) compared with @entity7 + < 2.0 x 10(6)/kg (median 75 days, P = 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

title: Quantitative XXXX analysis may be used to guide peripheral blood stem cell harvests.

answer: @entity7


abstract: BACKGROUND: We report the use of an ex vivo precision cut liver slice (PCLS) @entity0 model for studying @entity2 . In this system, liver tissue is unfixed, unfrozen, and alive for maintenance in culture and subsequent molecular analysis. METHODS AND FINDINGS: Using thick naive @entity0 liver tissue and sterile culture conditions, the addition of soluble egg antigen (SEA) derived from @entity6 eggs, followed 4, 24 and 48hrs time points. Tissue was collected for transcriptional analysis and supernatants collected to quantitate liver enzymes, cytokines and chemokines. No significant hepatotoxicity was demonstrated by supernatant liver enzymes due to the presence of SEA. A proinflammatory response was observed both at the transcriptional level and at the protein level by cytokine and chemokine bead assay. Key genes observed elevated transcription in response to the addition of SEA included: @entity3 and @entity4 , @entity5 , all associated with @entity1 . The recruitment of antigen presenting cells was reflected in increases in transcription of @entity11 , @entity14 and @entity9 . Indications of tissue remodeling were seen in elevated gene expression of various Matrix MetalloProteinases ( @entity13 , 9, 10, 13) and delayed increases in @entity7 . Collagen deposition was significantly reduced in the presence of SEA as shown in @entity8 expression by qPCR after 24hrs culture. Cytokine and chemokine analysis of the culture supernatants confirmed the elevation of proteins including @entity5 , @entity10 , @entity14 and @entity12 . CONCLUSIONS: This ex vivo model system for the synchronised delivery of parasite antigen to liver tissue provides an insight into the early phase of @entity2 , corresponding with the release of soluble proteins from dying schistosome eggs.

title: An Ex Vivo Model for Studying XXXX and the Effect of Released Protein from Dying Eggs.

answer: @entity2


abstract: BACKGROUND AND PURPOSE: @entity4 ions act as endogenous vasodilators of the cerebral circulation and act pharmacologically as noncompetitive antagonists of the @entity3 receptor by virtue of their role as endogenous voltage-sensitive blockers of the ion channel. The preclinical efficacy of @entity4 has been demonstrated in standard models of @entity1 . METHODS: Sixty @entity0 were randomized to @entity5 (8 mmol IV over 15 minutes and 65 mmol over 24 hours) or placebo within 12 hours of clinically diagnosed @entity6 . Pulse, blood pressure, and serum @entity4 levels were monitored. Primary outcome was @entity2 or significant functional impairment (Barthel Index score < 60) at 3 months. RESULTS: @entity4 was well tolerated, with no significant adverse effects and no change in blood pressure or pulse rate. Laboratory and electrocardiographic variables did not differ significantly between placebo- and @entity4 -treated groups. Serum @entity4 rose from 0.76 mmol/L to 1.42 mmol/L over 24 hours and remained significantly higher than in the placebo group at 48 hours. Thirty percent of @entity4 -treated and 40% of placebo-treated @entity0 were dead or disabled (Barthel Index score < 60) at 3 months (P = .42). There was a decrease in the number of early deaths in the @entity4 -treated group (P = .066, log-rank test). CONCLUSIONS: @entity5 is well tolerated after @entity1 and has no deleterious hemodynamic effects at this dose. Further trials are required to determine efficacy.

title: A randomized, double-blind, placebo-controlled pilot trial of intravenous @entity5 in XXXX .

answer: @entity1


abstract: BACKGROUND AND PURPOSE: @entity4 ions act as endogenous vasodilators of the cerebral circulation and act pharmacologically as noncompetitive antagonists of the @entity3 receptor by virtue of their role as endogenous voltage-sensitive blockers of the ion channel. The preclinical efficacy of @entity4 has been demonstrated in standard models of @entity1 . METHODS: Sixty @entity0 were randomized to @entity5 (8 mmol IV over 15 minutes and 65 mmol over 24 hours) or placebo within 12 hours of clinically diagnosed @entity6 . Pulse, blood pressure, and serum @entity4 levels were monitored. Primary outcome was @entity2 or significant functional impairment (Barthel Index score < 60) at 3 months. RESULTS: @entity4 was well tolerated, with no significant adverse effects and no change in blood pressure or pulse rate. Laboratory and electrocardiographic variables did not differ significantly between placebo- and @entity4 -treated groups. Serum @entity4 rose from 0.76 mmol/L to 1.42 mmol/L over 24 hours and remained significantly higher than in the placebo group at 48 hours. Thirty percent of @entity4 -treated and 40% of placebo-treated @entity0 were dead or disabled (Barthel Index score < 60) at 3 months (P = .42). There was a decrease in the number of early deaths in the @entity4 -treated group (P = .066, log-rank test). CONCLUSIONS: @entity5 is well tolerated after @entity1 and has no deleterious hemodynamic effects at this dose. Further trials are required to determine efficacy.

title: A randomized, double-blind, placebo-controlled pilot trial of intravenous XXXX in @entity1 .

answer: @entity5


abstract: AIM: To parse out the impact of advanced ageing and disuse on skeletal muscle function, we utilized both in  vivo and in  vitro techniques to comprehensively assess upper- and lower-limb muscle contractile properties in 8 young (YG; 25      6  years) and 8 oldest-old mobile (OM; 87      5  years) and 8 immobile ( @entity3 ; 88      4  years) @entity0 . METHODS: In vivo, maximal @entity2 (MVC), electrically evoked @entity1 ( @entity1 ), and physiological cross-sectional area (PCSA) of the quadriceps and elbow flexors were assessed. Muscle biopsies of the vastus lateralis and biceps brachii facilitated the in  vitro assessment of single fibre-specific tension (Po). RESULTS: In vivo, compared to the young, both the OM and @entity3 exhibited a more pronounced loss of MVC in the lower limb [OM (-60%) and @entity3 (-75%)] than the upper limb (OM  =  -51%; @entity3  =  -47%). Taking into account the reduction in muscle PCSA (OM  =  -10%; @entity3  =  -18%), only evident in the lower limb, by calculating voluntary muscle-specific force, the lower limb of the @entity3 (-40%) was more compromised than the OM (-13%). However, in  vivo, @entity1 in both upper and lower limbs (approx. 9.8  N  m  cm(-2) ) and Po (approx. 123  mN  mm(-2) ), assessed in  vitro, implies preserved intrinsic contractile function in all muscles of the oldest-old and were well correlated (r  =  0.81). CONCLUSION: These findings suggest that in the oldest-old, neither advanced ageing nor disuse, per se, impacts intrinsic skeletal muscle function, as assessed in  vitro. However, in  vivo, muscle function is attenuated by age and exacerbated by disuse, implicating factors other than skeletal muscle, such as neuromuscular control, in this diminution of function.

title: In vivo and in vitro evidence that intrinsic upper- and lower-limb skeletal muscle function is unaffected by ageing and disuse in oldest-old XXXX .

answer: @entity0


abstract: PURPOSE: To characterize the sagittal alignment of each Lenke type and investigate the relationship between coronal and @entity1 in adolescent idiopathic scoliotic (AIS) @entity0 . METHODS: A cohort of 184 subjects with AIS was retrospectively recruited. Radiographic data were measured and collected, including the Lenke types, Cobb angles of structural curves, and sagittal spino-pelvic parameters. Subjects were grouped according to their genders, Lenke curve types, lumbar modifiers and the amount of coronal structural curves. The sagittal alignment was then compared between the different groups, and correlation analysis was also taken between coronal and sagittal parameters. Besides, each subject's Roussouly type was decided and its distribution was compared among different Lenke types. RESULTS: The cohort included 59 males and 125 females, averagely aged at 15.5      3.3  years old. Most sagittal parameters except @entity2 ( @entity2 ) and pelvic tilt (PT) were similar among different Lenke types, while all the sagittal parameters were similar between males and females. The groups with different lumbar modifiers had similar sagittal parameters except @entity2 , which was also true for the groups with different amounts of coronal curves. 42.4  % of the cohort belonged to Roussouly type 3, and the distribution of Roussouly types was comparable among all Lenke types. All sagittal parameters except C7 translation ratio were significantly different among Roussouly types (P  <  0.05). Correlation analysis showed that main thoracic (MT) was negatively correlated with @entity3 ( @entity3 , r  =  -0.324), sacral slope (r  =  -0.321) and spino-sacral angle (r  =  -0.363). Partial correlation analysis found that thoracolumbar/lumbar was negatively correlated with @entity2 (r  =  -0.464) and @entity3 (r  =  -0.422) when MT was controlled. CONCLUSIONS: The influence of @entity1 on sagittal parameters was limited and mainly reflected in the deviation of @entity2 . Most coronal and sagittal parameters were not significantly correlated, and the @entity1 types did not change the global sagittal postural patterns.

title: Analysis of the relationship between coronal and XXXX in adolescent idiopathic scoliosis.

answer: @entity1


abstract: BACKGROUND: The initiation and timely completion of the @entity1 ) vaccine in young @entity0 is critical. We compared the initiation and completion of the HPV vaccine among @entity0 in 2 community-based networks with electronic health records: 1 with a prompt and reminder system (prompted cohort) and 1 without (unprompted cohort). METHODS: Female @entity0 aged 9 to 26 years seen between @entity2 , 2007, and January 25, 2010, were used as the retrospective cohort. @entity0 demographics and vaccination dates were extracted from the electronic health records. RESULTS: @entity0 eligible for the vaccine included 6019 from the prompted cohort and 9096 from the unprompted cohort. Mean age at initiation was 17.3 years in the prompted cohort and 18.1 years in the unprompted cohort. Significantly more (P < .001) @entity0 initiated the vaccine in the prompted cohort (34.9%) compared with the unprompted cohort (21.5%). African Americans aged 9 to 18 years with >= 3 visits during the observation period were significantly more likely to initiate in the prompted cohort (P < .001). The prompted cohort was significantly more likely (P < .001) to complete the vaccine series in a timely manner compared with the unprompted cohort. CONCLUSION: More @entity0 aged 9 to 26 years initiated and achieved timely completion of the HPV vaccine series in clinics using an electronic health record system with prompts compared with clinics without prompts.

title: Impact of an Electronic Health Record (EHR) Reminder on XXXX ) Vaccine Initiation and Timely Completion.

answer: @entity1


abstract: PURPOSE: We studied ultrasound-guided percutaneous cryoablation for treatment of @entity3 . MATERIALS AND METHODS: Our series includes 83 individuals who underwent transrectal ultrasound-guided transperineal percutaneous cryoablation of the prostate. @entity6 levels, biopsy results and complications were assessed at 3 months. RESULTS: Of 61 biopsies 8 (13.1%) were positive for @entity2 (half showed stage D disease). Of @entity0 with stages T1 to T3 @entity1 92.6% were free of disease at 3 months. @entity6 levels were significantly decreased by an average of 1.90 ng./ml. (p < 0.05). Major complications were infrequent, including @entity7 in 1 @entity0 , urethral strictures in 3, @entity8 and partial @entity4 in 2. @entity5 was frequent but transient. CONCLUSIONS: Transrectal ultrasound-guided transperineal percutaneous cryoablation of the prostate produces few major complications and appears at 3 months to be effective in eradicating @entity3 . Longer followup is required to test the original hypothesis.

title: Transrectal ultrasound-guided transperineal cryoablation in the treatment of XXXX : preliminary results.

answer: @entity3


abstract: RATIONALE AND OBJECTIVES: To investigate the correlation between prevalence and degree of @entity6 ( @entity6 ) and extracoronary calcifications (ECCs), scored quantitatively according to Agatston and semiquantitatively by visual analysis, in chest computed tomography (CT) studies obtained for @entity1 screening in asymptomatic subjects and in @entity0 with known @entity4 ( @entity4 ), and to compare the association of ECC and @entity6 to established cardiovascular risk factors. MATERIALS AND METHODS: Prospective study on 501 males (67      8  years) with a history of working dust exposure who underwent nongated low-dose chest CT for @entity1 screening. Of these, 63 (12.6%) had a history of @entity4 , the remaining 438 subjects (87.4%) were clinically asymptomatic and without a history of @entity4 . On the day of the CT study, subjects underwent a thorough clinical examination including blood tests and completed a standardized questionnaire to establish a complete medical history. ECC and @entity6 scores were quantified according to Agatston and, in addition, by visual rating of @entity5 load of individual vessel territories on a five-point scale from "absent" to "extensive." Results were correlated with the respective subjects' cardiovascular risk factors and with the presence or absence of @entity4 . RESULTS: ECC scores correlated significantly with @entity6 scores (two-sided Spearman 0.515; P  <  .001). ECC scores were associated significantly (P  <  .001) with cardiovascular risk factors (smoking history, @entity3 , @entity2 , and @entity7 ) and with subjects' Framingham/prospective cardiovascular m  nster study scores, whereas @entity6 scores were associated only with the presence of @entity7 . @entity6 scores were strongly associated with @entity4 than ECC scores (area under the curve, 0.88 vs. 0.66 at receiver operating characteristic analysis). Visual scoring of ECC/ @entity6 load correlated closely with the respective Agatston values (P  <  .001) and revealed the same association (or lack thereof) with cardiovascular risk factors/ @entity4 . CONCLUSIONS: In nongated low-dose CT for @entity1 screening, @entity6 and ECC load can be accurately established by visual analysis. ECC and @entity6 scores correlate closely, but not perfectly. There is a strong association between established cardiovascular risk factors and ECC load, but not @entity6 load, providing further evidence that ECC scoring may complement @entity6 scoring for broader risk assessment, for example, regarding prediction of extracoronary vascular events.

title: Extracoronary Thoracic and Coronary Artery Calcifications on Chest CT for XXXX Screening: Association with Established Cardiovascular Risk Factors - The "CT-Risk" Trial.

answer: @entity1


abstract: The @entity5 / @entity10 / @entity9 (ICE) combination represents an active chemotherapy regimen across a wide variety of disease types. The most common limiting @entity1 for all three of these agents individually and in combination is myelosuppression. Thus, this regimen represents an ideal model to evaluate the role of @entity8 support in amelioration of hematologic @entity1 , maintenance of dose intensity, and dose escalation. While chemotherapy strategies using colony-stimulating factors have abrogated @entity7 , cumulative @entity3 is common with many chemotherapy regimens, including ICE chemotherapy. In preclinical and phase II trials, monotherapy with recombinant @entity0 @entity2 ( @entity2 ) has demonstrated substantial thrombopoietic activity, but with little enhancement of neutrophil recovery. Thus, this study was designed to evaluate combination cytokine therapy with both recombinant @entity2 and @entity6 ( @entity6 ) after ICE chemotherapy. Previously untreated @entity0 with inoperable @entity4 are eligible. Treatment includes two monthly cycles of @entity5 2,000 mg/m2 with mesna 1,600 mg/m2 intravenously on days 1, 2, and 3, @entity10 350 mg/m2 intravenously on day 1 only, and @entity9 75 mg/m2 intravenously on days 1, 2, and 3. All @entity0 then receive @entity6 at a dose of 5 micrograms/kg/d subcutaneously beginning on day 4 until a postnadir absolute neutrophil count of more than 10 x 10(9)/L. Cohorts of @entity0 (n = 15) are randomized to receive 0, 1, 2.5, or 5 micrograms/kg/d of @entity2 subcutaneously on days 4 to 13 in successive cohorts. This study has now reached its target accrual in all cohorts. The final data analysis is in progress. It is hoped that this trial will define the safety and tolerability of the simultaneous administration of @entity2 and @entity6 following ICE chemotherapy in @entity0 with @entity4 . In addition, this trial should determine the biologic activity and hematopoietic recovery observed during the simultaneous administration of these two cytokines in this setting.

title: The role of hematopoietic growth factors in support of @entity5 / XXXX / @entity9 chemotherapy.

answer: @entity10


abstract: The @entity5 / @entity10 / @entity9 (ICE) combination represents an active chemotherapy regimen across a wide variety of disease types. The most common limiting @entity1 for all three of these agents individually and in combination is myelosuppression. Thus, this regimen represents an ideal model to evaluate the role of @entity8 support in amelioration of hematologic @entity1 , maintenance of dose intensity, and dose escalation. While chemotherapy strategies using colony-stimulating factors have abrogated @entity7 , cumulative @entity3 is common with many chemotherapy regimens, including ICE chemotherapy. In preclinical and phase II trials, monotherapy with recombinant @entity0 @entity2 ( @entity2 ) has demonstrated substantial thrombopoietic activity, but with little enhancement of neutrophil recovery. Thus, this study was designed to evaluate combination cytokine therapy with both recombinant @entity2 and @entity6 ( @entity6 ) after ICE chemotherapy. Previously untreated @entity0 with inoperable @entity4 are eligible. Treatment includes two monthly cycles of @entity5 2,000 mg/m2 with mesna 1,600 mg/m2 intravenously on days 1, 2, and 3, @entity10 350 mg/m2 intravenously on day 1 only, and @entity9 75 mg/m2 intravenously on days 1, 2, and 3. All @entity0 then receive @entity6 at a dose of 5 micrograms/kg/d subcutaneously beginning on day 4 until a postnadir absolute neutrophil count of more than 10 x 10(9)/L. Cohorts of @entity0 (n = 15) are randomized to receive 0, 1, 2.5, or 5 micrograms/kg/d of @entity2 subcutaneously on days 4 to 13 in successive cohorts. This study has now reached its target accrual in all cohorts. The final data analysis is in progress. It is hoped that this trial will define the safety and tolerability of the simultaneous administration of @entity2 and @entity6 following ICE chemotherapy in @entity0 with @entity4 . In addition, this trial should determine the biologic activity and hematopoietic recovery observed during the simultaneous administration of these two cytokines in this setting.

title: The role of hematopoietic growth factors in support of XXXX / @entity10 / @entity9 chemotherapy.

answer: @entity5


abstract: The @entity5 / @entity10 / @entity9 (ICE) combination represents an active chemotherapy regimen across a wide variety of disease types. The most common limiting @entity1 for all three of these agents individually and in combination is myelosuppression. Thus, this regimen represents an ideal model to evaluate the role of @entity8 support in amelioration of hematologic @entity1 , maintenance of dose intensity, and dose escalation. While chemotherapy strategies using colony-stimulating factors have abrogated @entity7 , cumulative @entity3 is common with many chemotherapy regimens, including ICE chemotherapy. In preclinical and phase II trials, monotherapy with recombinant @entity0 @entity2 ( @entity2 ) has demonstrated substantial thrombopoietic activity, but with little enhancement of neutrophil recovery. Thus, this study was designed to evaluate combination cytokine therapy with both recombinant @entity2 and @entity6 ( @entity6 ) after ICE chemotherapy. Previously untreated @entity0 with inoperable @entity4 are eligible. Treatment includes two monthly cycles of @entity5 2,000 mg/m2 with mesna 1,600 mg/m2 intravenously on days 1, 2, and 3, @entity10 350 mg/m2 intravenously on day 1 only, and @entity9 75 mg/m2 intravenously on days 1, 2, and 3. All @entity0 then receive @entity6 at a dose of 5 micrograms/kg/d subcutaneously beginning on day 4 until a postnadir absolute neutrophil count of more than 10 x 10(9)/L. Cohorts of @entity0 (n = 15) are randomized to receive 0, 1, 2.5, or 5 micrograms/kg/d of @entity2 subcutaneously on days 4 to 13 in successive cohorts. This study has now reached its target accrual in all cohorts. The final data analysis is in progress. It is hoped that this trial will define the safety and tolerability of the simultaneous administration of @entity2 and @entity6 following ICE chemotherapy in @entity0 with @entity4 . In addition, this trial should determine the biologic activity and hematopoietic recovery observed during the simultaneous administration of these two cytokines in this setting.

title: The role of hematopoietic growth factors in support of @entity5 / @entity10 / XXXX chemotherapy.

answer: @entity9


abstract: BACKGROUND: Rapid, accurate and high-throughput identification of vector arthropods is of paramount importance in surveillance programmes that are becoming more common due to the changing geographic occurrence and extent of many @entity4 . Protein profiling by MALDI-TOF mass spectrometry fulfils these requirements for identification, and reference databases have recently been established for several vector taxa, mostly with specimens from laboratory colonies. METHODS: We established and validated a reference database containing 20 phlebotomine sand @entity1 (Diptera: Psychodidae, Phlebotominae) species by using specimens from colonies or field-collections that had been stored for various periods of time. RESULTS: Identical biomarker mass patterns ('superspectra') were obtained with colony- or field-derived specimens of the same species. In the validation study, high quality spectra (i.e. more than 30 evaluable masses) were obtained with all fresh insects from colonies, and with 55/59 insects deep-frozen (liquid @entity3 /-80    C) for up to 25  years. In contrast, only 36/52 specimens stored in @entity2 could be identified. This resulted in an overall sensitivity of 87 % (140/161); specificity was 100 %. Duration of storage impaired data counts in the high mass range, and thus cluster analyses of closely related specimens might reflect their storage conditions rather than phenotypic distinctness. A major drawback of MALDI-TOF @entity0 is the restricted availability of in-house databases and the fact that mass spectrometers from 2 companies (Bruker, Shimadzu) are widely being used. We have analysed fingerprints of phlebotomine sand flies obtained by automatic routine procedure on a Bruker instrument by using our database and the software established on a Shimadzu system. The sensitivity with 312 specimens from 8 sand @entity1 species from laboratory colonies when evaluating only high quality spectra was 98.3 %; the specificity was 100 %. The corresponding diagnostic values with 55 field-collected specimens from 4 species were 94.7 % and 97.4 %, respectively. CONCLUSIONS: A centralized high-quality database (created by expert taxonomists and experienced users of mass spectrometers) that is easily amenable to customer-oriented identification services is a highly desirable resource. As shown in the present work, spectra obtained from different specimens with different instruments can be analysed using a centralized database, which should be available in the near future via an online platform in a cost-efficient manner.

title: Identification of phlebotomine sand flies using one MALDI-TOF XXXX reference database and two mass spectrometer systems.

answer: @entity0


abstract: BACKGROUND: Fever and @entity9 (FN) is a common complication of @entity1 treatment, but hospital utilization patterns for this condition are not well described. METHODS: Data were analyzed from the Kids' Inpatient Database (KID), an all-payer US hospital database, for 2009. Pediatric FN @entity0 were identified using: age  <=19  years, urgent or emergent admit type, non-transferred, and a combination of ICD-9-CM codes for @entity3 and @entity9 . Sampling weights were used to permit national inferences. RESULTS: @entity1 @entity0 accounted for 1.5 % of pediatric hospital discharges in 2009 (n   =   110,967), with 10.1 % of @entity1 -related discharges meeting FN criteria (n   =   11,261). Two-fifths of FN discharges had a "short length of stay" ( @entity7 ) of  <=3  days, which accounted for approximately  65.5 million in hospital charges. @entity10 (6.0 %) and @entity6 ( @entity6 ) (3.7 %) were the most common @entity5 associated with @entity7 . Factors significantly associated with @entity7 included living in the Midwest region (OR   =   1.65, 1.22-2.24) or West region (OR 1.54, 1.11-2.14) versus Northeast, having a diagnosis of @entity6 (OR   =   1.39, 1.03-1.87) or @entity11 (OR   =   1.63, 1.18-2.25) versus those without those comorbidities, and having a soft tissue @entity4 (OR   =   1.47, 1.05-2.04), @entity8 (OR   =   2.33, 1.62-3.35), or an @entity2 (OR   =   1.76, 1.05-2.95) compared with @entity0 without these diagnoses. CONCLUSION: FN represents a common precipitant for hospitalizations among @entity1 @entity0 . @entity7 admissions are rarely associated with serious @entity5 , but contribute substantially to the burden of hospitalization for pediatric FN.

title: Hospital discharges for @entity3 and XXXX in @entity1 @entity0 : United States, 2009.

answer: @entity9


abstract: BACKGROUND: Fever and @entity9 (FN) is a common complication of @entity1 treatment, but hospital utilization patterns for this condition are not well described. METHODS: Data were analyzed from the Kids' Inpatient Database (KID), an all-payer US hospital database, for 2009. Pediatric FN @entity0 were identified using: age  <=19  years, urgent or emergent admit type, non-transferred, and a combination of ICD-9-CM codes for @entity3 and @entity9 . Sampling weights were used to permit national inferences. RESULTS: @entity1 @entity0 accounted for 1.5 % of pediatric hospital discharges in 2009 (n   =   110,967), with 10.1 % of @entity1 -related discharges meeting FN criteria (n   =   11,261). Two-fifths of FN discharges had a "short length of stay" ( @entity7 ) of  <=3  days, which accounted for approximately  65.5 million in hospital charges. @entity10 (6.0 %) and @entity6 ( @entity6 ) (3.7 %) were the most common @entity5 associated with @entity7 . Factors significantly associated with @entity7 included living in the Midwest region (OR   =   1.65, 1.22-2.24) or West region (OR 1.54, 1.11-2.14) versus Northeast, having a diagnosis of @entity6 (OR   =   1.39, 1.03-1.87) or @entity11 (OR   =   1.63, 1.18-2.25) versus those without those comorbidities, and having a soft tissue @entity4 (OR   =   1.47, 1.05-2.04), @entity8 (OR   =   2.33, 1.62-3.35), or an @entity2 (OR   =   1.76, 1.05-2.95) compared with @entity0 without these diagnoses. CONCLUSION: FN represents a common precipitant for hospitalizations among @entity1 @entity0 . @entity7 admissions are rarely associated with serious @entity5 , but contribute substantially to the burden of hospitalization for pediatric FN.

title: Hospital discharges for XXXX and @entity9 in @entity1 @entity0 : United States, 2009.

answer: @entity3


abstract: BACKGROUND: Fever and @entity9 (FN) is a common complication of @entity1 treatment, but hospital utilization patterns for this condition are not well described. METHODS: Data were analyzed from the Kids' Inpatient Database (KID), an all-payer US hospital database, for 2009. Pediatric FN @entity0 were identified using: age  <=19  years, urgent or emergent admit type, non-transferred, and a combination of ICD-9-CM codes for @entity3 and @entity9 . Sampling weights were used to permit national inferences. RESULTS: @entity1 @entity0 accounted for 1.5 % of pediatric hospital discharges in 2009 (n   =   110,967), with 10.1 % of @entity1 -related discharges meeting FN criteria (n   =   11,261). Two-fifths of FN discharges had a "short length of stay" ( @entity7 ) of  <=3  days, which accounted for approximately  65.5 million in hospital charges. @entity10 (6.0 %) and @entity6 ( @entity6 ) (3.7 %) were the most common @entity5 associated with @entity7 . Factors significantly associated with @entity7 included living in the Midwest region (OR   =   1.65, 1.22-2.24) or West region (OR 1.54, 1.11-2.14) versus Northeast, having a diagnosis of @entity6 (OR   =   1.39, 1.03-1.87) or @entity11 (OR   =   1.63, 1.18-2.25) versus those without those comorbidities, and having a soft tissue @entity4 (OR   =   1.47, 1.05-2.04), @entity8 (OR   =   2.33, 1.62-3.35), or an @entity2 (OR   =   1.76, 1.05-2.95) compared with @entity0 without these diagnoses. CONCLUSION: FN represents a common precipitant for hospitalizations among @entity1 @entity0 . @entity7 admissions are rarely associated with serious @entity5 , but contribute substantially to the burden of hospitalization for pediatric FN.

title: Hospital discharges for @entity3 and @entity9 in XXXX @entity0 : United States, 2009.

answer: @entity1


abstract: BACKGROUND: Fever and @entity9 (FN) is a common complication of @entity1 treatment, but hospital utilization patterns for this condition are not well described. METHODS: Data were analyzed from the Kids' Inpatient Database (KID), an all-payer US hospital database, for 2009. Pediatric FN @entity0 were identified using: age  <=19  years, urgent or emergent admit type, non-transferred, and a combination of ICD-9-CM codes for @entity3 and @entity9 . Sampling weights were used to permit national inferences. RESULTS: @entity1 @entity0 accounted for 1.5 % of pediatric hospital discharges in 2009 (n   =   110,967), with 10.1 % of @entity1 -related discharges meeting FN criteria (n   =   11,261). Two-fifths of FN discharges had a "short length of stay" ( @entity7 ) of  <=3  days, which accounted for approximately  65.5 million in hospital charges. @entity10 (6.0 %) and @entity6 ( @entity6 ) (3.7 %) were the most common @entity5 associated with @entity7 . Factors significantly associated with @entity7 included living in the Midwest region (OR   =   1.65, 1.22-2.24) or West region (OR 1.54, 1.11-2.14) versus Northeast, having a diagnosis of @entity6 (OR   =   1.39, 1.03-1.87) or @entity11 (OR   =   1.63, 1.18-2.25) versus those without those comorbidities, and having a soft tissue @entity4 (OR   =   1.47, 1.05-2.04), @entity8 (OR   =   2.33, 1.62-3.35), or an @entity2 (OR   =   1.76, 1.05-2.95) compared with @entity0 without these diagnoses. CONCLUSION: FN represents a common precipitant for hospitalizations among @entity1 @entity0 . @entity7 admissions are rarely associated with serious @entity5 , but contribute substantially to the burden of hospitalization for pediatric FN.

title: Hospital discharges for @entity3 and @entity9 in @entity1 XXXX : United States, 2009.

answer: @entity0


abstract: UNASSIGNED: Damage of small nerve fibers may lead to a large variety of clinical symptoms. Small-fiber @entity0 underlies the symptoms of @entity1 , which may decrease quality of life. It also contributes to the poor prognosis of @entity1 because it plays a key role in the pathogenesis of foot ulceration and @entity2 . Impairment of small nerve fibers is considered the earliest alteration in the course of @entity1 . Therefore, assessment of functional and morphological @entity3 may enable timely diagnosis. The definition, symptoms, and clinical significance of small-fiber @entity0 are considered in the present review. An apparently more complex interaction between small-fiber impairment and microcirculation is extensively discussed. Diagnostic modalities include morphometric and functional methods. Corneal confocal microscopy and punch skin biopsy are considered gold standards, but noninvasive functional tests are also diagnostically useful. However, in routine clinical practice, small-fiber @entity0 is diagnosed by its typical clinical presentation. Finally, prompt treatment should be initiated following diagnosis.

title: XXXX : A Diabetic Microvascular Complication of Special Clinical, Diagnostic, and Prognostic Importance.

answer: @entity3


abstract: General frameworks of the @entity0 screening process are available, but none directly compare the process in detail across different organ sites. This limits the ability of medical and public health professionals to develop and evaluate coordinated screening programs that apply resources and population management strategies available for one @entity0 site to other sites. We present a trans-organ conceptual model that incorporates a single screening episode for breast, cervical, and @entity1 into a unified framework based on clinical guidelines and protocols; the model concepts could be expanded to other organ sites. The model covers four types of care in the screening process: risk assessment, detection, diagnosis, and treatment. Interfaces between different provider teams (eg, primary care and specialty care), including communication and transfer of responsibility, may occur when transitioning between types of care. Our model highlights across each organ site similarities and differences in steps, interfaces, and transitions in the screening process and documents the conclusion of a screening episode. This model was developed within the National @entity0 Institute-funded consortium Population-based Research Optimizing Screening through Personalized Regimens (PROSPR). PROSPR aims to optimize the screening process for breast, cervical, and @entity1 and includes seven research centers and a statistical coordinating center. Given current health care reform initiatives in the United States, this conceptual model can facilitate the development of comprehensive quality metrics for @entity0 screening and promote trans-organ comparative @entity0 screening research. PROSPR findings will support the design of interventions that improve screening outcomes across multiple @entity0 sites.

title: Unifying Screening Processes Within the PROSPR Consortium: A Conceptual Model for Breast, Cervical, and XXXX .

answer: @entity1


abstract: INTRODUCTION: Endocan-1 has been proposed as a possible biomarker and predictor of vascular endothelial related pathologies. Thus, we hypothesised that Endocan-1 levels would be up-regulated in maternal plasma and placentae from @entity0 with @entity2 . The aim of our study was to compare Endocan-1 concentrations in maternal/fetal plasma and placentae from normotensive and pre-eclamptic pregnancies. METHODS: Observational and case-controlled study, at the S  o Lucas Hospital, Brazil. Placental biopsies, maternal/umbilical venous (fetal) plasma were taken from 67 normotensive and 50 pre-eclamptic @entity0 . Endocan-1 levels were quantified using MagPlex(TH)-C and analysed by Analysis of Covariance and Pearson correlation. The null hypothesis was rejected at p<0.05. RESULTS: Higher levels of Endocan-1 were found in maternal plasma in the pre-eclamptic group (mean ratio=1.49; 95% confidence interval: 1.19-1.85, p=0.001), with a moderate effect size (Cohen's D=0.84). Placental Endocan-1 levels ( g/g) were lower in @entity2 (1.52 [1.10, 2.40] vs. 2.24 [1.32, 3.75], p=0.033) and fetal Endocan-1 concentration (ng/ml) did not show any difference between groups (3.10 [2.60, 4.54] vs. 2.91 [2.20, 3.66] p=0.085). In addition, an up-regulation of maternal plasma Endocan-1 in the pre-eclamptic group was observed when stratified in relation to gestational age, systolic blood pressure and @entity1 (p<0.05, for all). Furthermore, a positive correlation between Endocan-1 concentration in maternal vs. fetal plasma was also found (r=0.258, p=0.015). For the matched samples, a negative correlation between Endocan-1 in maternal/fetal plasma with birthweights, placental weights and gestational age at delivery was observed (p<0.05 for all). DISCUSSION: Endocan-1 is increased in @entity0 with @entity2 for all strata, which highlight the importance of this molecule as a possible biomarker. The negative correlations between Endocan-1 and clinical data suggest that this molecule may also be involved with prematurity and low birth weight, which warrants further investigations.

title: Endocan-1 concentrations in maternal and fetal plasma and placentae in XXXX in the third trimester of pregnancy.

answer: @entity2


abstract: We analyzed the relation between @entity4 trough levels (ELISA: @entity0 1-41, IMx: @entity0 42-70) and rejection and/or @entity5 episodes, retrospectively, in the first 70 consecutive cases of living related liver transplantation. Twenty @entity0 (28.6%) had rejection episodes. Of the 13 @entity0 who had evidence of rejection during the first 3 months, 6 @entity0 without @entity2 and 7 @entity0 with @entity5 showed low concentrations of @entity4 (< 5 ng/ml). Twelve @entity0 were treated and improved with high dose @entity1 administration and an increase in the @entity4 dosage. One @entity0 died of refractory rejection. Nine @entity0 had evidence of rejection after the first 3 months. In 3 @entity0 , weaning from @entity4 initiated the rejection episodes. Five @entity0 repeated rejection and 4 @entity0 required a third immunosuppressant ( @entity3 ). @entity5 included @entity6 (11 cases), EBV (13 cases), @entity8 cases), and @entity7 case). Excess immunosuppression might have been the cause, but no clear correlation was found. We propose that the optimal dosage of @entity4 obtained by monitoring the trough levels using the IMx method should maintain a 10-20 ng/ml level during the first month, and a 5-10 ng/ml level at the second and third months.

title: A proposal of XXXX optimal dosing in living related liver transplantations.

answer: @entity4


abstract: Esophageal intubation with a plastic prosthesis is a well established palliative treatment for @entity5 . The technique is safer with endoscopy than previous surgical techniques. Advantages of stent include rapid and long lasting relief of @entity7 in most @entity0 with @entity3 esophagus. Repeated procedures are not required. Placement of prosthesis is the treatment of choice in BEF. Cost is less compared to other palliative modalities such as laser. SEMS have distinct advantages over conventional prosthesis as they may be inserted with less @entity2 and fewer complications. Diet needs occasionally to be limited to soft or blenderized foods to prevent occlusion. A disadvantage of uncovered SEMS is short duration of palliation due to @entity1 ingrowth which can be overcome with availability of covered SEMS. Starvation is the most common cause of @entity4 in @entity0 with @entity1 . Prosthesis combats deterioration and leads to rapid @entity6 . Overall, single time procedure without general anaesthesia, short hospital stay and immediate improvement in @entity7 are considerable gains.

title: Esophageal prosthesis in palliation of XXXX .

answer: @entity1


abstract: UNASSIGNED: Venous Leg Ulceration (VLU) is a chronic condition for which healthcare systems worldwide face rising treatment costs. VLU can be due to @entity2 which causes the veins to become cuffed with fibrin, inhibiting the supply of nutrients to the wound site. For @entity0 that cannot tolerate compression therapy with an inelastic short stretch (SS) bandage, the mainstay treatment, an elastic three layered (3L) bandage is an alternative. In this paper, a mathematical model is developed to investigate whether the healing of @entity3 under SS and 3L bandages occurs at different rates and to postulate the reason for any difference. The two treatments were applied to a simplified wound geometry, under the assumption that the rate limiting step of healing is the supply of @entity1 to the wounded tissue. Clinical data of wound size over time under the two treatments from Weller et al. (2012) was used to fit key, unknown, model parameters using a least squares approach. Numerical results are presented for the @entity1 distribution within the wound space, using the fitted parameter values. The 3L bandage allows more @entity1 flow into the wound than the SS bandage and, hence, the 3L bandage results in faster healing, however the difference is more significant for wounds of larger initial size. The model can be used as a predictive tool in a clinical setting to estimate the time to heal for a wound of a given initial size, treated with either a SS or 3L bandage.

title: Healing of XXXX using compression therapy: Predictions of a mathematical model.

answer: @entity3


abstract: The aim of the present study was to investigate whether or not charybdotoxin (CAS 95751-30-7, @entity3 ), a selective and potent @entity0 -dependent K+ channel blocker, inhibits the relaxation of @entity1 tracheal smooth muscle induced by pituitary adenylate cyclase activating polypeptides with 27 residues ( @entity4 ) and with 38 residues ( @entity4 ). Two forms of PACAP were discovered in hypothalamic tissues, and are known to increase the tissues @entity2 levels and to be independent of beta-adrenoceptors. The relaxant effects of these polypeptides were evaluated by measuring the isometric tension of tracheal smooth muscle of @entity1 in vitro. Both forms of PACAP showed dose-dependent relaxant effects. The pD2 of @entity4 was 7.01 +/- 0.04 and that of @entity4 was 6.43 +/- 0.05. ChTX (10(-12)-3 x 10(-9) mol/l) did not affect the resting tension of the @entity1 tracheal smooth muscle. ChTX (10(-8) mol/l) slightly increased the tension, in some experiments being considered as a phasic tension change. ChTX (10(-8) mol/l) caused a small but significant rightward shift in the concentration-response curves of @entity4 and @entity4 . ChTX decreased the pD2 of @entity4 to 6.74 +/- 0.03 and that of @entity4 to 6.25 +/- 0.04. These results suggest that @entity2 -mediated activation of @entity0 -dependent K+ channels may play an important role in the relaxation of the @entity1 tracheal smooth muscle induced by both forms of PACAP as well as beta-agonist.

title: Inhibition of pituitary adenylate cyclase activating polypeptide induced relaxation of XXXX tracheal smooth muscle by charybdotoxin.

answer: @entity1


abstract: @entity4 ( @entity4 ) is an @entity1 characterized by progressive childhood-onset @entity8 , @entity12 , @entity9 and @entity10 of the conjunctivae. Further symptoms may be @entity3 and frequent infections, and an increased risk of @entity0 . As well as this classic manifestation, several other non-classic forms exist, including milder or incomplete @entity4 phenotypes caused by homozygous or compound heterozygous mutations in the @entity11 gene. Recently, @entity11 mutations have been found in 13 Canadian Mennonites with early-onset, @entity7 , in a French family with generalized @entity5 and in an Indian family with @entity6 . In this article, we will describe a Turkish family with three affected sibs. Their phenotypes range from pure cervical @entity5 associated with hand @entity2 to truncal and more generalized dystonic postures. Exome sequencing has revealed the potentially pathogenic compound heterozygous variants @entity13 and @entity14 in the @entity11 gene. The variants segregated perfectly with the phenotypes within the family. Both mutations detected in @entity11 have been shown to be pathogenic, and the a-fetoprotein, a marker of @entity4 , was found to be increased. This report supports recent literature showing that @entity11 mutations are not exclusively associated with @entity4 but may also cause a more, even intra-familial variable phenotype in particular in association with @entity5 .

title: Clinical variability in XXXX .

answer: @entity4


abstract: We report the results of medial physeal stapling in 16 knees with @entity4 and 27 with @entity4 . In the primary group, stapling was undertaken at a mean chronological age of 12 years in @entity0 and 13 years in @entity0 . The medial femoral physis was stapled in ten knees and the medial femoral and tibial physes in six knees. At skeletal maturity, all @entity0 had excellent or good leg alignment. @entity4 is due to @entity1 , @entity2 , or to @entity3 . Stapling was at a mean chronological age of 11 years in @entity0 and 14 years in @entity0 . The medial femoral physis was stapled in 13 knees, the medial tibial physis in three and both in 11 knees. At skeletal maturity, 85% had excellent or good leg alignment, and correction had occurred within one year. Two of the poor results were due to staple extrusion from osteoporotic bone, and two to overcorrection. Rebound growth was minimal and unpredictable after the removal of staples. Medial physeal stapling is a suitable method of treatment for both primary and @entity4 in late childhood and in adolescence. At least one year of knee growth is required to achieve correction, and care is needed to avoid overcorrection of the @entity4 .

title: Medial physeal stapling for primary and XXXX in late childhood and adolescence.

answer: @entity4


abstract: BACKGROUND: A previous individual @entity0 data meta-analysis by the Meta-Analysis of Chemotherapy in @entity2 (MAC-NPC) collaborative group to assess the addition of chemotherapy to radiotherapy showed that it improves overall survival in @entity2 . This benefit was restricted to @entity0 receiving concomitant chemotherapy and radiotherapy. The aim of this study was to update the meta-analysis, include recent trials, and to analyse separately the benefit of concomitant plus adjuvant chemotherapy. METHODS: We searched PubMed, Web of Science, Cochrane Controlled Trials meta-register, ClinicalTrials.gov, and meeting proceedings to identify published or unpublished randomised trials assessing radiotherapy with or without chemotherapy in @entity0 with non-metastatic @entity2 and obtained updated data for previously analysed studies. The primary endpoint of interest was overall survival. All trial results were combined and analysed using a fixed-effects model. The statistical analysis plan was pre-specified in a protocol. All data were analysed on an intention-to-treat basis. FINDINGS: We analysed data from 19 trials and 4806 @entity0 . Median follow-up was 7  7 years (IQR 6  2-11  9). We found that the addition of chemotherapy to radiotherapy significantly improved overall survival (hazard ratio [HR] 0  79, 95% CI 0  73-0  86, p<0  0001; absolute benefit at 5 years 6  3%, 95% CI 3  5-9  1). The interaction between treatment effect (benefit of chemotherapy) on overall survival and the timing of chemotherapy was significant (p=0  01) in favour of concomitant plus adjuvant chemotherapy (HR 0  65, 0  56-0  76) and concomitant without adjuvant chemotherapy (0  80, 0  70-0  93) but not adjuvant chemotherapy alone (0  87, 0  68-1  12) or induction chemotherapy alone (0  96, 0  80-1  16). The benefit of the addition of chemotherapy was consistent for all endpoints analysed (all p<0  0001): progression-free survival (HR 0  75, 95% CI 0  69-0  81), locoregional control (0  73, 0  64-0  83), distant control (0  67, 0  59-0  75), and @entity1 mortality (0  76, 0  69-0  84). INTERPRETATION: Our results confirm that the addition of concomitant chemotherapy to radiotherapy significantly improves survival in @entity0 with locoregionally advanced @entity2 . To our knowledge, this is the first analysis that examines the effect of concomitant chemotherapy with and without adjuvant chemotherapy as distinct groups. Further studies on the specific benefits of adjuvant chemotherapy after concomitant chemoradiotherapy are needed. FUNDING: French Ministry of Health (Programme d'actions int  gr  es de recherche VADS), Ligue Nationale Contre le @entity1 , and Sanofi-Aventis.

title: Chemotherapy and radiotherapy in XXXX : an update of the MAC-NPC meta-analysis.

answer: @entity2


abstract: Proliferation of some cultured @entity0 @entity1 cell lines bearing high numbers of @entity7 ( @entity7 ) receptors is paradoxically inhibited by @entity7 in nanomolar concentrations. In the present study, we have investigated the biochemical mechanism of growth inhibition in A431 @entity0 @entity3 cells exposed to exogenous @entity7 . In parallel, we studied a selected subpopulation, @entity10 , which is resistant to @entity7 -mediated growth inhibition. We observed a marked reduction in @entity8 ( @entity8 ) activity when A431 and A431-F cells were cultured with 20 nM @entity7 for 4 h. After further continuous exposure of A431 cells to @entity7 , the @entity8 activity remained at a low level and was accompanied by persistent @entity5 . In contrast, the early reduced @entity8 activity and G1 accumulation in A431-F cells was only transient. We found that, at early time points (4-8 h), @entity7 induces @entity4 / @entity4 mRNA and protein expression in both @entity7 -sensitive A431 cells and @entity7 -resistant A431-F cells. But only in A431 cells, was @entity4 / @entity4 expression sustained at a significantly increased level for up to 5 d after addition of @entity7 . Induction of @entity4 / @entity4 by @entity7 could be inhibited by a specific @entity7 receptor @entity2 kinase inhibitor, @entity9 , suggesting that @entity4 / @entity4 induction was a consequence of receptor @entity2 kinase activation by @entity7 . We also demonstrated that the increased @entity4 / @entity4 was associated with both @entity8 and @entity6 ( @entity6 ). Taken together, our results demonstrate that @entity4 / @entity4 is an important mediator of @entity7 -induced @entity5 and growth inhibition in A431 cells.

title: Prolonged induction of XXXX / @entity4 / @entity8 / @entity6 complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition.

answer: @entity4


abstract: Proliferation of some cultured @entity0 @entity1 cell lines bearing high numbers of @entity7 ( @entity7 ) receptors is paradoxically inhibited by @entity7 in nanomolar concentrations. In the present study, we have investigated the biochemical mechanism of growth inhibition in A431 @entity0 @entity3 cells exposed to exogenous @entity7 . In parallel, we studied a selected subpopulation, @entity10 , which is resistant to @entity7 -mediated growth inhibition. We observed a marked reduction in @entity8 ( @entity8 ) activity when A431 and A431-F cells were cultured with 20 nM @entity7 for 4 h. After further continuous exposure of A431 cells to @entity7 , the @entity8 activity remained at a low level and was accompanied by persistent @entity5 . In contrast, the early reduced @entity8 activity and G1 accumulation in A431-F cells was only transient. We found that, at early time points (4-8 h), @entity7 induces @entity4 / @entity4 mRNA and protein expression in both @entity7 -sensitive A431 cells and @entity7 -resistant A431-F cells. But only in A431 cells, was @entity4 / @entity4 expression sustained at a significantly increased level for up to 5 d after addition of @entity7 . Induction of @entity4 / @entity4 by @entity7 could be inhibited by a specific @entity7 receptor @entity2 kinase inhibitor, @entity9 , suggesting that @entity4 / @entity4 induction was a consequence of receptor @entity2 kinase activation by @entity7 . We also demonstrated that the increased @entity4 / @entity4 was associated with both @entity8 and @entity6 ( @entity6 ). Taken together, our results demonstrate that @entity4 / @entity4 is an important mediator of @entity7 -induced @entity5 and growth inhibition in A431 cells.

title: Prolonged induction of @entity4 / XXXX / @entity8 / @entity6 complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition.

answer: @entity4


abstract: Proliferation of some cultured @entity0 @entity1 cell lines bearing high numbers of @entity7 ( @entity7 ) receptors is paradoxically inhibited by @entity7 in nanomolar concentrations. In the present study, we have investigated the biochemical mechanism of growth inhibition in A431 @entity0 @entity3 cells exposed to exogenous @entity7 . In parallel, we studied a selected subpopulation, @entity10 , which is resistant to @entity7 -mediated growth inhibition. We observed a marked reduction in @entity8 ( @entity8 ) activity when A431 and A431-F cells were cultured with 20 nM @entity7 for 4 h. After further continuous exposure of A431 cells to @entity7 , the @entity8 activity remained at a low level and was accompanied by persistent @entity5 . In contrast, the early reduced @entity8 activity and G1 accumulation in A431-F cells was only transient. We found that, at early time points (4-8 h), @entity7 induces @entity4 / @entity4 mRNA and protein expression in both @entity7 -sensitive A431 cells and @entity7 -resistant A431-F cells. But only in A431 cells, was @entity4 / @entity4 expression sustained at a significantly increased level for up to 5 d after addition of @entity7 . Induction of @entity4 / @entity4 by @entity7 could be inhibited by a specific @entity7 receptor @entity2 kinase inhibitor, @entity9 , suggesting that @entity4 / @entity4 induction was a consequence of receptor @entity2 kinase activation by @entity7 . We also demonstrated that the increased @entity4 / @entity4 was associated with both @entity8 and @entity6 ( @entity6 ). Taken together, our results demonstrate that @entity4 / @entity4 is an important mediator of @entity7 -induced @entity5 and growth inhibition in A431 cells.

title: Prolonged induction of @entity4 / @entity4 / XXXX / @entity6 complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition.

answer: @entity8